Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients
Investigating the Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients: A Pilot, Randomized Double-blinded, Sham-controlled Trial
The goal of this clinical trial is to learn if acupuncture works to treat non-erosive reflux disease (NERD) patients. The main questions it aims to answer are:
- Electroacupuncture (EA) is superior to sham EA in terms of easing the symptom severity of NERD.
- Acupuncture is able to influence gastrointestinal function, autonomic regulation, and stress responses in NERD patients.
Participants will:
- Receive acupuncture treatment twice per week for 6 weeks.
- Leave plasma, serum, saliva, stool, and urine samples at baseline, mid-treatment, and end-of-treatment.
- Complete patient-reported-outcomes (PROs) at baseline, mid-treatment, and end-of-treatment
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Linda LD Zhong, PhD
- Numéro de téléphone: +65 67911744
- E-mail: linda.zhong@ntu.edu.sg
Sauvegarde des contacts de l'étude
- Nom: Huangyan Chen
- Numéro de téléphone: +65 97663672
- E-mail: huangyan001@e.ntu.edu.sg
Lieux d'étude
-
-
-
Singapore, Singapour, S637551
- Nanyang Technological University, School of Biological Sciences
-
Contact:
- Huangyan Chen
- Numéro de téléphone: +65 97663672
- E-mail: huangyan001@e.ntu.edu.sg
-
Contact:
- Linda LD Zhong, PhD
- Numéro de téléphone: +65 65921733
- E-mail: linda.zhong@ntu.edu.sg
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults aged 21 to 75 years at the time of consent;
- Presence of heartburn, regurgitation or chest pain before screening with a frequency of at least twice a week;
- No evidence of esophageal mucosal injury on endoscopy within the past 5 years;
- GERD-Q score ≥8 (indicating active GERD symptoms);
- Ability and willingness to provide written informed consent to participate.
Exclusion Criteria:
-
Structural or organic gastrointestinal disease, including but not limited to:
- gastrointestinal malignancy,
- eosinophilic esophagitis,
- esophageal stricture, varices, or infections,
- active peptic ulcer disease,
- gastric or duodenal tumors;
-
Presence of alarming symptoms (e.g. severe dysphagia, hematemesis, unexplained weight loss, or hematochezia, etc.);
-
History of digestive tract surgery or esophageal interventions, including chemotherapy, radiotherapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy;
-
Use of prohibited medical treatment:
- acupuncture treatment on the abdomen and chest within past 1 month,
- concomitant medication affecting gastrointestinal motility or visceral sensitivity (antidiarrheals, antidepressants, narcotic analgesics, anticholinergics, etc.),
- antibiotics, prebiotics, probiotics, or immunosuppressants within 1 month prior to screening;
-
Presence of an implanted cardiac pacemaker;
-
History of hypersensitivity to acupuncture, or needle phobia;
-
Severe psychiatric illness (e.g. schizophrenia, major depression, dementia), cognitive impairment, or other conditions likely to compromise adherence to study procedures;
-
Pregnant or breastfeeding;
-
Current participation in other clinical trials that could interfere with study outcomes.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Electroacupuncture (EA)
The WHO Standardized Acupuncture Points Location will be used to identify the location of these acupoints: ST36 Zusanli, PC6 Neiguan, CV12 Zhongwan, LR3 Taichong, SP4 Gongsun; and auxiliary acupoints added according to symptom severity: PC7 Daling, ST44 Neiting, EX-HN3 Yintang, ST37 Shangjuxu, SP6 Sanyinjiao, LU7 Lieque. After sterilizing the skin, needles of 0.25 mm in diameter and 25-40 mm in length will be inserted into the acupoints to a depth of 10-30 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 2/100 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min. |
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore. |
|
Comparateur factice: Sham-electroacupuncture (SEA)
The sham electroacupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 B-cun away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. Insertion depth will be approximately less than 10 mm. The electrostimulator will not be switched on for these patients. All needles will be removed after 30 min of needle retention. |
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Gastroesophageal Reflux Disease Questionnaire (GERDQ)
Délai: From enrollment to the end of follow-up at 16 weeks
|
≥ 50% reduction in total GERD-Q score or normalization (<8) |
From enrollment to the end of follow-up at 16 weeks
|
|
Gastrointestinal Symptom Rating scale (GSRS)
Délai: From enrollment to the end of follow-up at 16 weeks
|
≥ 0.5 point decrease in mean GSRS Reflux domain value |
From enrollment to the end of follow-up at 16 weeks
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
Délai: From enrollment to the end of follow-up at 16 weeks
|
≥ 0.5 point improvement on the mean QOLRAD score |
From enrollment to the end of follow-up at 16 weeks
|
|
Euro QoL (EQ-5D-5L)
Délai: From enrollment to the end of follow-up at 16 weeks
|
change in index utility |
From enrollment to the end of follow-up at 16 weeks
|
|
Hospital Anxiety and Depression Scale (HADS)
Délai: From enrollment to the end of follow-up at 16 weeks
|
categorical shift from ≥ 11 to < 11 or ≥ 8 to < 8, or ≥ 1.5 point reduction per HADS-A and HADS-D subscale |
From enrollment to the end of follow-up at 16 weeks
|
|
Visceral Sensitivity Index (VSI)
Délai: From enrollment to the end of follow-up at 16 weeks
|
≥ 15% reduction from baseline |
From enrollment to the end of follow-up at 16 weeks
|
|
Esophageal Hypervigilance and Anxiety Scale (EHAS) Short Form
Délai: From enrollment to the end of follow-up at 16 weeks
|
≥ 15% reduction from baseline |
From enrollment to the end of follow-up at 16 weeks
|
|
Simplified Constitution of Chinese Medicine Questionnaire (CCMQ)
Délai: At baseline
|
At baseline
|
|
|
Traditional Chinese medicine functional gastrointestinal disorders syndrome scale (TCM-FGID)
Délai: From enrollment to the end of follow-up at 16 weeks
|
(Total syndrome score before treatment - Total syndrome score after treatment) / Total syndrome score before treatment × 100% |
From enrollment to the end of follow-up at 16 weeks
|
|
Bang's blinding index (BBI)
Délai: End of first week and sixth week of intervention
|
End of first week and sixth week of intervention
|
|
|
James' blinding index (JBI)
Délai: End of first week and sixth week of intervention
|
End of first week and sixth week of intervention
|
|
|
Patient's global impression of change (PGIC)
Délai: From mid-treatment to the end of follow-up at 16 week
|
From mid-treatment to the end of follow-up at 16 week
|
|
|
Daily patient diary
Délai: From enrollment to the end of follow-up at 16 weeks
|
From enrollment to the end of follow-up at 16 weeks
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Linda LD Zhong, PhD, Nanyang Technological University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- IRB-2025-1138
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
IPD sharing will be available upon request.
Délai de partage IPD
Data will become available within 7 years after completion of the clinical trial.
Critères d'accès au partage IPD
Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .